Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
In patients with everolimus-eluting stents (EES), continuing dual antiplatelet therapy (DAPT) beyond 2 y offers no additional protection against major adverse cardiac and cerebral events (MACCE) compared to stopping DAPT at 2 y.
Why this matters
Although DAPT is common after EES implantation, there is no consensus on how long the therapy should be continued.
742 patients underwent successful percutaneous coronary intervention (PCI) with EES and were free from MACCE at 2 y post PCI.
591 of those received DAPT for 2 y and 151 received DAPT for ≤2 y.
3 y follow-up.
Funding: None disclosed.
After adjusting for baseline differences, 145 patients from each group were propensity matched.